• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Application of CTL Therapy as a Cancer Immunotherapy

Research Project

Project/Area Number 10044300
Research Category

Grant-in-Aid for Scientific Research (B).

Allocation TypeSingle-year Grants
Section一般
Research Field 広領域
Research InstitutionKochi Medical School

Principal Investigator

FUJIMOTO Shigeyoshi  Kochi Medical School, Faculty of Medicine, Professor, 医学部・免疫学, 教授 (00009151)

Co-Investigator(Kenkyū-buntansha) TAKATA Masaru  Kochi Medical School, Faculty of Medicine, Assistant Professor, 医学部, 講師 (80136374)
SHEN Yuan  Kochi Medical School, Faculty of Medicine, Research Associate, 医学部, 助手 (50294830)
HAMASATO Shinji  Kochi Medical School, Faculty of Medicine, Research Associate, 医学部, 助手 (60228533)
ジュストリシィ ロザリオ  カタニア大学, 医学部, 教授
マルチェリーノ ルチオ・  ローマ大学, 医学部, 教授
Project Period (FY) 1998 – 1999
Project Status Completed (Fiscal Year 1999)
Budget Amount *help
¥6,700,000 (Direct Cost: ¥6,700,000)
Fiscal Year 1999: ¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 1998: ¥4,000,000 (Direct Cost: ¥4,000,000)
KeywordsCancer immunotherapy / CTL therapy / Immune cell transfer
Research Abstract

The head investigator (Prof. Shigeyoshi Fujimoto) and his research group have been developing cytotoxic T lymphocyte (CTL) therapy against cancer as a cancer specific immunotherapy. Since our results of CTL therapy were reported in International symposiums, International Cancer Congresses, and International Immunology Congresses, many medical investigators were interested in our CTL therapy, and offered research collaboration to us. CTL therapy is essentially based on the procedure of in vitro CIL induction in peripheral mononuclear cells of cancer patients stimulated by attenuated autologous cancer cells in 7 day stimulation culture. Once CTL is activated the activated mononuclear cells including activated CTL are given intravenously once a week repeatedly, resulted in tumor dormancy. We have been collaborating with Prof. Lucio R. Marcellino's research group in Department of Oncosurgery, Faculty of medicine, University of Rome "La Sapienza" for application of CTL therapy to various ty … More pe of malignant tumors since 1995. From the beginning of April, 1998 to the end of March, 2000, we performed the following activities using this grant. (1) From October 18 to November 2, 1998, the head investigator and Dr. Y. Shen visited Prof. Marcellino of Department of Oncosurgery, Univ. Rome "La Sapienza" and presented our new basic development concerning CTL therapy to improve efficacy of the therapy in various associated hospitals in Rome, Velletri, Civitavecchia and San Marino Republic. A major point of the new development was that we found Th2 type CD4 helper T cell subset capable of rejecting syngeneic tumor in tumor growing mice. We are going to apply this finding for human system. During our stay in Rome, we participated and presented in an International Symposium on "Predictive Oncology and Therapy" which was held in Nice, France from October 24-28, 1998. (2)Fchruary, 1999 we invited Prof. Marcellino, Dr. G. Ghironzi (Director of San Marino state hospital), and Dr. R. Nonni (Chief of Gastrointestinal Department in a villa Maria group hospital at Largo) to the 3ィイD1rdィエD1 annual meeting of "Cancer Specific Immunotherapy" in Tokyo organized by the head investigator and to our lab, Department of Immunology, Kochi Medical School to inspect our facility for CTL therapy. (3)From October 23-27ィイD1thィエD1, 1999, the head investigator, Dr. Y. Shen, and Dr. T. Fu participated in the International Immunology Congress held in Shanghai to present our new data (4)From November 11-21, 1999, the head investigator visited Prof. Marcellino in Rome and several villa Maria Group hospitals at Ravenna to exchange our latest information and discuss a new direction of our collaborative research work concerning CTL therapy. (5)November 11-13, 1999, we invited two young oncologists in the Cancer Institute of Catholic University of Rome by a recommendation of Prof. Marcellino to the 4th annual meeting of "Cancer Specific Immunotherapy" in Tokyo organized by the head of investigator to exchange scientific medical information of cancer immunotherapy. Less

Report

(3 results)
  • 1999 Annual Research Report   Final Research Report Summary
  • 1998 Annual Research Report
  • Research Products

    (11 results)

All Other

All Publications (11 results)

  • [Publications] Yan Jiao: "Sequential T cell response involved in tumor rejection of sarcoma,meth A,in syngeneic mice"Japanese Journal Cancer Research. 89・6. 657-665 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Shigeyoshi Fujimoto: "CD8/CD14 ratio:A new immunologicl parameter predicting the efficacy of cancer therapy"Annals of Cancer Research and Therapy. 7・2. 65-70 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Tihui Fu: "Tumor-specific CD^<4+> suppressor T cell cline capable of inhibiting the rejection of syngeneic sarcoma in A/J mice"International Journal of Cancer. (印刷中). (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] 藤本 重義: "新しい癌免疫化学療法の指針-QOLを重視した癌薬物療法"医薬ジャーナル社. 291(分担8ページ) (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Yan Jiao, Shen Yuan, and Shigeyoshi Fujimoto: "Sequential T cell response involved in tumor rejection of sarcoma, meth A, in syngeneic mice."Japanese Journal Cancer Research. Vol. 89, No. 6. 657-665 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Shigeyoshi Fujimoto, and Shinji hamasato: "CD8/CD14 ratio: A new immunological parameter predicting the efficacy of cancertherapy"Annals of Cancer Research and Therapy. Vol. 7, No. 2. 65-70 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Tihui Fu, Shen Yuan, and Shigeyoshi Fujimoto: "Tumor-specific CD4ィイD1+ィエD1 suppressor T cell clone capable of inhibiting the rejection of syngeneic sarcoma in A/J mice."International Journal of Cancer. in press. (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Shigeyoshi Fujimoto: "Indication of a new cancer immunotherapy -QOL oriented cancer drugtherapy -CIL therapy against cancer as a cancer specific immunotherapy"Iyaku Journal Press. 1999. 211 (204)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Yan Jiao: "Sequential T cell response involved in tumor rejection of sarcoma,meth A,in syngeneic mice."Japanese Journal Cancer Research. 89・6. 657-665 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] Shigeyoshi Fujimoto: "CD8/CD14 ratio:A new immunologicl parameter predicting the efficacy of cancer therapy."annals of Cancer Research and Therapy. 7・2. 65-70 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] 藤本 繁義: "新しい癌免疫化学療法の指針-QOLを重視した癌薬物療法"医薬ジャーナル社. 291 (1999)

    • Related Report
      1999 Annual Research Report

URL: 

Published: 1998-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi